CN104678103A - 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 - Google Patents
检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 Download PDFInfo
- Publication number
- CN104678103A CN104678103A CN201410772665.4A CN201410772665A CN104678103A CN 104678103 A CN104678103 A CN 104678103A CN 201410772665 A CN201410772665 A CN 201410772665A CN 104678103 A CN104678103 A CN 104678103A
- Authority
- CN
- China
- Prior art keywords
- detection
- afp
- fetoprotein
- alpha
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 78
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 title claims abstract description 26
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 title claims abstract description 26
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 title claims abstract description 26
- 239000000126 substance Substances 0.000 title claims abstract description 11
- 102000006830 Luminescent Proteins Human genes 0.000 title abstract 3
- 108010047357 Luminescent Proteins Proteins 0.000 title abstract 3
- 210000002966 serum Anatomy 0.000 claims abstract description 91
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 239000011521 glass Substances 0.000 claims abstract description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 4
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 117
- 230000033581 fucosylation Effects 0.000 claims description 39
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 32
- 229960002685 biotin Drugs 0.000 claims description 18
- 239000011616 biotin Substances 0.000 claims description 18
- 235000020958 biotin Nutrition 0.000 claims description 16
- 239000012895 dilution Substances 0.000 claims description 13
- 238000010790 dilution Methods 0.000 claims description 13
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 12
- 108090001008 Avidin Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 230000009871 nonspecific binding Effects 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
- 230000012447 hatching Effects 0.000 claims description 5
- 238000004020 luminiscence type Methods 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000012898 sample dilution Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 abstract description 2
- 238000002331 protein detection Methods 0.000 abstract description 2
- 108010034897 lentil lectin Proteins 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 63
- 201000007270 liver cancer Diseases 0.000 description 28
- 208000014018 liver neoplasm Diseases 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000012417 linear regression Methods 0.000 description 6
- 239000012925 reference material Substances 0.000 description 6
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 235000005489 dwarf bean Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 125000003147 glycosyl group Chemical group 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000504 luminescence detection Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 101710153593 Albumin A Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 101710085718 Defensin-like protein 3 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- -1 blank Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/00527—Sheets
- B01J2219/00533—Sheets essentially rectangular
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
- B01J2219/00614—Delimitation of the attachment areas
- B01J2219/00621—Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00603—Making arrays on substantially continuous surfaces
- B01J2219/00659—Two-dimensional arrays
- B01J2219/00662—Two-dimensional arrays within two-dimensional arrays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/00693—Means for quality control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
- B01J2219/00725—Peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
- G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plasma & Fusion (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明涉及检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法,属于蛋白检测技术。其特征在于:所述蛋白芯片的基质载片上至少包括一个检测亚区,一个所述检测亚区检测一份血清样品;所检测亚区内设置有2个检测斑区域和1个排对照斑区域,其中一个检测斑区域有固定甲胎蛋白的特异性抗体形成的检测斑,另一个检测斑区域有固定小扁豆素形成的检测斑,所述对照斑区域有固定牛血清白蛋白形成的对照斑;同一个检测斑区域内的所有检测斑上的物质的浓度相同。本发明的蛋白芯片,试剂盒和方法能够准确、高通量地检测血清糖蛋白岩藻糖指数,临床使用中,具有灵敏度高、省时、便捷、经济等优点。
Description
技术领域
本发明涉及蛋白检测技术,特别涉及一种检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片及检测方法。
背景技术
原发性肝癌与肝炎、肝硬变等良性肝病产生的甲胎蛋白(alpha fetoprotein,AFP)在其糖链结构上存在很大差异,即与良性肝病相比,肝癌产生的AFP,其岩藻糖指数要高得多。岩藻糖具有与小扁豆素结合的特性。AFP根据其(岩藻糖基)对小扁豆凝集素的亲和力不同可以分为AFP-L1、AFP-L2和AFP-L3。其中AFP-L1主要来自于良性肝病,AFP-L2主要来源于孕妇,而AFP–L3是甲胎蛋白的岩藻糖糖基化形式,主要来源于HCC。2005年FDA正式批准将AFP-L3作为原发性肝癌的标志物之一。AFP-L3在肝癌的早期诊断、鉴别诊断、疗效评估和预后监测等方面均具有较高的特异性与敏感性。
岩藻糖为甲基化六碳糖,存在于组织及血清多种糖蛋白糖链中,称为蛋白结合岩藻糖(protein-bound fucose,P-bf)。AFP碳水化合物链上存在岩藻糖残基,此种异质体称为岩藻糖基化AFP(FucAFP),其占AFP总量的百分率称为岩藻糖基化指数(Fucosylation Index,Fuol)。岩藻糖基化指数具有重要的理论意义和临床应用意义,在肝癌诊断和预后应用中可以作为一项重要的指标。
传统的血清岩藻糖蛋白分离方法,包括亲和免疫交叉电泳技术,亲和印迹法,亲和层析法、“双位点夹心”酶联免疫吸附法、LiBASys测定仪、检测系统技术及热景生物糖基捕获离心柱前处理技术。其中植物凝集素亲和免疫电泳技术和i30检测系统技术要求高、操作繁琐、试剂昂贵,限制了其推广应用。而糖基捕获离心柱,由于样本处理和检测分开进行,增加了操作的繁琐性。
发明内容
本发明基于本领域在血清中AFP与AFP-L3的定量检测技术的需求及空白,提供了一种适合于定量检测生物样品中甲胎蛋白和/或岩藻糖基化甲胎蛋白的试剂盒及检测方法,该方案不仅仅适合于检测血清中的AFP抗原,对检测其他岩藻糖基化蛋白具有通用性,具有省时、经济、准确、便捷的优点。
本发明的技术方案如下:
一种检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片,其特征在于:所述蛋白芯片的基质载片上至少包括一个检测亚区,一个所述检测亚区检测一份血清样品;
所检测亚区内设置有2个检测斑区域和1个排对照斑区域,其中一个检测斑区域有固定甲胎蛋白的特异性抗体形成的检测斑,另一个检测斑区域有固定小扁豆素形成的检测斑,所述对照斑区域有固定牛血清白蛋白形成的对照斑;
同一个检测斑区域内的所有检测斑上的物质的浓度相同。
所述一个检测斑区域至少包括两个所述检测斑。
所述甲胎蛋白的特异性抗体为鼠抗人甲胎蛋白抗体。
所述基质载片上具有多个所述检测亚区,所述每个检测斑区域包括排列成1排的4个检测斑,所述对照斑区域包括排列成1排的4个对照斑;所述检测斑和对照斑排成平行的三列。
所述检测亚区之间设置有凸起作为物理隔断。
一种检测血清糖蛋白岩藻糖指数的化学发光试剂盒,其特征在于:包括权利要求1~4任一所述的化学发光蛋白芯片。
还包括AFP标准品,生物素标记的AFP多克隆抗体,亲和素HRP和HRP化学发光底物液;所述生物素标记的AFP多克隆抗体为兔源抗体,与所述检测斑上固定的AFP特异性抗体来源于不同物种。
还包括用于洗涤和稀释的常规试剂PBST和PBS。
上述任一试剂盒在检测甲胎蛋白和/或岩藻糖基化甲胎蛋白和/或血清糖蛋白岩藻糖指数方面的应用。
一种定量检测岩藻糖基化蛋白的方法,其特征在于:采用上述任一化学发光蛋白芯片,包括如下步骤:
(1)样品检测
将待测血清样本稀释后滴加在所述化学发光蛋白芯片的检测亚区上,孵育后,用PBST洗涤检测亚区,去除非特异结合物;
加入用PBS稀释的生物素标记的AFP抗体,孵育后,用PBST洗涤,去除非特异结合物;
加入PBS稀释的亲和素HRP,孵育后,用PBST洗涤,去除非特异结合物。
加入HRP底物发光液,用化学发光扫描仪对蛋白芯片进行扫描,分别得到稀释后待测血清样本中的甲胎蛋白的发光像素值以及岩藻糖基化蛋白的发光像素值;
(2)获取甲胎蛋白标准曲线方程及岩藻糖基化蛋白的标准曲线方程:
所述甲胎蛋白标准曲线方程的横坐标x为AFP标准品的梯度浓度值;其纵坐标y为以剃度浓度的AFP标准品为系列待测样品,以步骤(1)的方法检测得到的甲胎蛋白的系列发光像素值;
所述岩藻糖基化蛋白标准曲线方程的横坐标x为AFP-L3标准品中AFP-L3的梯度浓度值;其纵坐标y为以剃度浓度的AFP-L3标准品为系列待测样品,以步骤(1)的方法检测得到的岩藻糖基化蛋白的系列发光像素值;所述AFP-L3标准品为含有岩藻糖基蛋白(AFP)的血清;
(3)步骤(1)中的待测血清样品的甲胎蛋白的发光像素值带入所述甲胎蛋白标准曲线方程中计算得到稀释后血清的甲胎蛋白浓度,乘以稀释倍数得到待测血清甲胎蛋白浓度;步骤(1)中的待测血清样品的岩藻糖基化蛋白的发光像素值带入所述岩藻糖基化蛋白标准曲线方程中计算得到稀释后的血清的岩藻糖基化蛋白浓度,乘以稀释倍数得到待测血清岩藻糖基化蛋白的浓度;
待测血清岩藻糖基化蛋白的浓度与所述待测血清甲胎蛋白浓度的比值岩藻糖基化指数。
所述孵育指37℃孵育30分钟。
本发明提供一种检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片,基于抗体抗原抗体夹心反应原理及化学发光原理,同时固定有甲胎蛋白特异性抗体和小扁豆素,甲胎蛋白特异性抗体用于结合血清中的所有甲胎蛋白(AFP-L1、AFP-L2和AFP-L3),小扁豆素用于结合岩藻糖基化甲胎蛋白。同时设置有对照斑点。可以在绝对相同的条件下同时检测到待测血清中甲胎蛋白总浓度以及岩藻糖基化甲胎蛋白的浓度,准确地获得血清糖蛋白岩藻糖指数。本发明提供的化学发光蛋白芯片至少包括一个亚检测区,可以检测一个血样。在大部分实施例中,优选设置至少两个检测亚区,其中一个亚区用于检测对照血清,另一个亚区用于检测待测血样。进一步地,为了实现高通量检测,优选为多个,例如,三个,四个,五个,六个,七个,八个,九个或十个检测亚区,这样就可以在一张芯片上检测多个血清样品,提高临床检测效率,降低成本。如图1所示,本发明的一个优选实施例中,一个所述检测亚区内包括4个固定有AFP特异性抗体的检测斑,4个固定有小扁豆素的检测斑和4个对照斑;两种检测斑和对照斑各排成平行的三列。
本发明还提供了一种检测血清糖蛋白岩藻糖指数的化学发光试剂盒,其中包括上述蛋白芯片以及化学发光的常规试剂,标准曲线方程数据等。
本发明蛋白质芯片的使用有三方面的优势:
一、在基本上完全相同的条件下检测岩血清中的甲胎蛋白和藻糖基化甲胎蛋白,以保证测得的岩藻糖基化指数更准确可靠。
二、允许同时检测多个样品。多个重复的样品,或者不同时间点取的样品以获得动态值,或者各个不同的样品,总之,实现高通量检测。整体上降低检测成本和提高检测效率。
三、采用本发明的蛋白质芯片需要的血样及抗体量都大为减少,仅需原始血清量2.5ul~10ul,而ELISA方法检测需血清50ul;蛋白芯片板抗体点样,5ul至少可以点样20张芯片,检测200份血清,抗体需要量远远低于ELISA方法,大大降低了检测成本和费用。
同时,本发明还提供了利用所述试剂盒对岩藻糖基化甲胎蛋白进行定量检测的方法。首先本发明采用购买的AFP抗原标准品,制成梯度浓度的待测AFP稀释液,通过化学发光检测方法测定每个梯度对应的发光像素值,以梯度浓度为横坐标,荧光像素值为纵坐标制定标准曲线并得到直线回归方程。
本发明提供的检测血清糖蛋白岩藻糖指数的方法,是在上述蛋白芯片上,利用抗体和抗原特异性结合,小扁豆素特异性结合的特点,加入血清或者血浆标本进行孵育,然后加入生物素标记的AFP多克隆抗体,HRP标记的亲和素,最后加入HRP发光底物,通过化学发光扫描仪对发光信号进行扫描量化。将获得的信号值带入预先制作好的直线回归方程中,得到样品中岩藻糖蛋白AFP-L3的浓度。
本发明的方法的检测原理与一般化学发光免疫反应有所区别,通常的化学发光免疫反应Elisa反应形成“抗体-抗原-辣根过氧化物酶标记的二抗”复合物,最后加入HRP化学发光底物液获得发光值。但是,由于辣根过氧化物酶本身是存在糖残基,如果在本发明中的二抗采用辣根过氧化物酶标记,辣根过氧化物酶的糖残基会结合小扁豆素,从而严重干扰检测值,本发明做过的一些实验证明,这样得不到准确的岩藻糖基化指数,假阳性非常高,正常血清都能测出很高的岩藻糖基化指数。基于此,本发明提供的芯片及方法的原理如下:将抗AFP单克隆抗体和小扁豆素有序的固定在蛋白芯片上,依次加入待测血清、生物素标记的AFP多克隆抗体和亲和素HRP,分别形成“AFP单抗-AFP-生物素标记AFP多抗-亲和素HRP复合物”,以及“小扁豆素-AFP-L3-生物素标记的AFP抗体-亲和素HRP复合物”,最后加入HRP化学发光底物液进行孵育,利用化学发光仪进行扫描得到发光像素值,将像素值代入标准曲线对应的直线回归方程式可分别得出AFP和AFP-L3的浓度,从而获得岩藻糖基化甲胎蛋白AFP-L3占AFP总量的百分率,即岩藻糖指数。
实验结果证明,本发明的方法不仅可以进行定性检测,还可通过发光强度对AFP和岩藻糖基化AFP进行定量检测。与ELISA方法进行对比,敏感性和特异性均优于ELISA方法,从时间上比较,ELISA检测至少需要3小时,本发明仅需要1.5小时;从抗体用量上比较,利用办发明的试剂盒中的蛋白质芯片进行抗体点样,5ul抗体至少可以点样20张芯片,检测200份血清,抗体需要量远远低于ELISA方法;从血清用量上比较,ELISA方法检测需血清50ul,而本发明的试剂盒和检测方法检测一份血清样品只需要2.5ul~10ul的原始血清量;因此,本发明提供的试剂盒和检测方法具有灵敏度高、省时、经济等特点,可以大大地降低血液蛋白检测的成本和时间。
综上,本发明的方法结合了化学发光检测方法、标准曲线以及蛋白芯片技术的应用,确保了利用试剂盒进行AFP-L3定量检测结果的高灵敏性,准确性、高效性和低成本。本发明提供的检测方法一种可行、可靠、经济,且简单、省时的方法。本发明的技术方案将为大规模、高通量检测血清中岩藻糖基化甲胎蛋白提供了一种经济、可靠的试剂盒和检测方法。
附图说明
图1.AFP/扁豆素蛋白质芯片点样示意图;
图2.AFP/扁豆素抗体夹心法蛋白质芯片流程图;
图3.AFP蛋白质芯片检测AFP标准品结果扫描图
蛋白芯片的点样抗体为不同浓度的AFP抗体,A:1mg/ml;B:0.5mg/ml;C:0.25mg/ml;检测物分别为1.80ng/ml,2.40ng/ml,3.20ng/ml,4.10ng/ml,5.5ng/ml,6.肝癌血清,7.肝癌血清,8.空白对照,9.健康血清,10.肝癌血清.
图4.AFP蛋白质芯片检测AFP3标准曲线图及回归方程a.
图5.AFP蛋白质芯片检测AFP标准品和血清样本扫描图。
检测物分别为,(1-5)80ng/ml,40ng/ml,20ng/ml,10ng/ml,5ng/ml,6.肝癌血清,7.肝癌血清,8肝癌血清,9肝癌血清,10肝癌血清(芯片抗体点样抗体为AFP 0.5mg/ml)
图6.AFP/扁豆素点样芯片,检测AFP-L3标准品结果扫描图
血清样本AFP-L3200ng/ml(血清号27)
图7.AFP/扁豆素点样芯片检测AFP-L3标准曲线图及回归方程b.
图8.AFP/扁豆素点样芯片检测肝癌和正常血清样本扫描图.
8张芯片,检测39份肝癌血清样本,32份正常健康血清样本,9份空白对照。
具体实施方式
下面结合具体实施方式对本发明作进一步的详细说明,但并不限制本发明的范围。如无特殊说明,下述实施例中使用的操作均为常规方法,所采用的试剂均可以商购获得。
主要仪器设备
化学发光扫描仪,由军事医学科学院研制。
主要试剂及其来源
鼠源单克隆抗体AFP(深圳菲鹏公司)、小扁豆素(Sigma公司)、醛基芯片(上海百傲公司)、生物素标记的兔源抗体、HRP标记的亲和素(美国abcam公司)、HRP化学发光底物液A液和B液,按照1:1比例混合,新鲜配置。(美国Millipore公司)。
实施例1蛋白质芯片制备及使用流程
实验所用试剂和仪器:鼠源单克隆抗体AFP(深圳菲鹏公司);小扁豆素(Sigma公司);醛基芯片(上海百傲公司);生物素标记的兔源一抗(美国abcam公司);HRP标记的亲和素(美国abcam公司),化学发光扫描仪。(军事医学科学院王升启教授实验室研制)
PBS配方:氯化钠(NaCl)8g,氯化钾(KCl)0.2g,磷酸氢二钠(Na2HPO4)1.44g,
磷酸二氢钾(KH2PO4)0.24g,调pH 7.4,定容1L
PBST配方:PBS,1L+Tween-20,1ml
芯片为醛基芯片(上海百傲公司),每张芯片包含10个检测方格(检测亚区),每个方格检测一份血清,一次检测10份血清。
每个检测方格内,将鼠源单克隆抗体AFP(深圳菲鹏公司)、小扁豆素Sigma公司)依次点在芯片上,点样四次,点样浓度单克隆抗体AFP 0.5mg/ml,小扁豆素4mg/ml,点成两排八个检测斑;10%牛血清白蛋白(BSA)作为阴性对照,同样点样四次,点成对照斑。
蛋白芯片操作流程:
用制备好的蛋白质芯片检测健康对照组和肝癌实验组动态血清标本中的肿瘤标志物。
用血清样本10ul,(或者2.5ul稀释4倍),滴加在芯片上,37℃孵育30分钟,利用抗原抗体相结合的特性,以及小扁豆素和岩藻糖结合的特性,使血清中的AFP与芯片上相对应的(鼠源)抗体特异性结合,形成抗原抗体(鼠源)复合物;小扁豆素与岩藻糖结合形成小扁豆素抗原复合物。
用PBST洗涤4次,去除非特异结合,再加入PBS稀释的生物素标记兔源一抗,37℃孵育30分钟。兔源抗体与抗原结合,形成鼠源抗体-AFP-兔源生物素标记抗体复合物,和小扁豆素-岩藻糖基化AFP-兔源生物素标记抗体复合物。
用PBST洗涤4次,去除非特异结合,再加入PBS稀释的亲和素HRP,37℃孵育30分钟。生物素与亲和素结合,形成“鼠源抗体-AFP-兔源生物素标记抗体-亲和素HRP复合物”,和“小扁豆素-岩藻糖基化AFP-兔源生物素标记抗体-亲和素HRP复合物”。
用PBST洗涤4次,去除非特异结合,加入HRP发光底物,37℃孵育30分钟,化学发光扫描仪进行扫描。
固相载体上的化学发光像素与标本中受检抗原的量成正向相关,此时测定复合物中的像素值,即可确定待测抗原含量。芯片点样抗体(鼠源一抗)和检测用的抗体(兔源一抗)分别取自不同种属的动物。如图示2抗体夹心法蛋白芯片流程图。
实施例2.本发明检测方法的建立
(1)标准曲线及回归方程式a
采用购买的AFP抗原(美国abcam公司),设置成不同的浓度梯度,(1-5)80ng/ml,40ng/ml,20ng/ml,10ng/ml,5ng/ml,6.肝癌血清,7.肝癌血清,8空白对照,9健康血清,10肝癌血清(图3,芯片抗体点样抗体为AFP 2mg/ml,1mg/ml,0.5mg/ml,0.25mg/ml)。
采用实施例1中的操作流程和蛋白质芯片检测AFP标准品各个浓度梯度,检测扫描结果见图3。检测结果绘制成标准曲线图,以标准物的浓度为横坐标,像素值为纵坐标,在坐标纸上绘出标准曲线。根据样品的像素值由标准曲线查出相应的浓度;再乘以稀释倍数;或用标准物的浓度与OD值计算出标准曲线的直线回归方程式,将样品的OD值代入方程式,计算出样品浓度,再乘以稀释倍数,即为样品的实际浓度,标准曲线及回归方程a见图4。
采用购买的AFP抗原(美国abcam公司),设置成不同的浓度梯度,(1-5)80ng/ml,40ng/ml,20ng/ml,10ng/ml,5ng/ml,6.肝癌血清,7.肝癌血清,8肝癌血清,9肝癌血清,10肝癌血清(图5,芯片抗体点样抗体为AFP 0.5mg/ml)。
采用实施例1中的操作流程和蛋白质芯片检测AFP标准品各个浓度梯度,检测扫描结果见图3。检测结果绘制成标准曲线图,以标准物的浓度为横坐标,像素值为纵坐标,在坐标纸上绘出标准曲线。根据样品的像素值由标准曲线查出相应的浓度;再乘以稀释倍数;或用标准物的浓度与OD值计算出标准曲线的直线回归方程式,将样品的OD值代入方程式,计算出样品浓度,再乘以稀释倍数,即为样品的实际浓度,标准曲线及回归方程a见图4。
(2)标准曲线及回归方程式b
采用已知AFP-L3浓度的血清,倍比稀释,设置成不同的浓度梯度,(1-5)200ng/ml,
100ng/ml,50ng/ml,25ng/ml,12.5ng/ml,(6-9)200ng/ml,100ng/ml,50ng/ml,25ng/ml.10空白对照(图6)。
采用实施例1中的操作流程和蛋白质芯片检测血清(AFP-L3)标准品各个浓度梯度,检测扫描结果见图6。检测结果绘制成标准曲线图,以标准物的浓度为横坐标,像素值为纵坐标,在坐标纸上绘出标准曲线。根据样品的像素值由标准曲线查出相应的浓度;再乘以稀释倍数;或用标准物的浓度与OD值计算出标准曲线的直线回归方程式,将样品的OD值代入方程式,计算出样品浓度,再乘以稀释倍数,即为样品的实际浓度,标准曲线及回归方程b见图7。
实施例3样品检测检验本发明方法的稳定性,准确性和可靠性
血清样本:
39份肝癌血清:来源于首都医科大学附属佑安医院标本库;
32份正常健康人血清;
9份空白对照(空白对照为1×PBS)。
检测流程同实施例1.
将样品的像素值代入图4的回归方程式a,计算出样品AFP浓度,再乘以稀释倍数,即为样品的AFP总浓度。将样品的像素值代入图7的回归方程式b,计算出样品AFP-L3浓度,再乘以稀释倍数,即为样品的AFP-L3总浓度。
每张芯片10个检测亚区,包括健康血清样本,肝癌血清样本,空白对照,具体分表1中芯片编号及检测亚区编号。
样品检测结果扫描结果见图8。
计算公式:AFP总浓度X={(扫描像素值Y-54.3)/4.75}×稀释倍数。
AFF-l3总浓度X={(扫描像素值Y-26.225)/2.17}×稀释倍数
AFP-L3指数=AFP-L3/AFP
检测结果如下表1.
表1临床样本检测结果汇总表。
注:HCC:肝癌血清;N:正常健康人血清;C:空白对照。—:未检测到阳性信号
目前的AFP检测水平以20ng/ml为分界线,正常人低于20ng/ml。AFP-L3(%)>10~15%为阳性判断指标。
本芯片的检测结果:
空白对照9份没有检测到AFP和AFP-L3:说明本实验采用的芯片有效。
健康血清32份,没有检测到AFP和AFP-L3;说明本发明提供的芯片及方法检测的假阳性为0。
肝癌血清39份:其中26份检测到AFP和AFP-L3,11份样本只检测到AFP,未检测到AFP-L3;2份样本既没有检测到AFP,也没有检测到AFP-L3。其中有4份肝癌血清标本的 AFP含量低于20ng/ml。21份肝癌血清样本的AFP-L3/AFP比例大于10%,5份样本的AFP-L3/AFP比例小于10%。证明:本发明的芯片和方法检出率为:(39-2-4)/39=84.6%,具有可靠的临床应用价值。上述数据说明,本发明的芯片和方法稳定性,准确性和可靠性良好
检测中遇到4份样本的AFP-L3/AFP比例大于1,是因为样品的AFP浓度过高,远远超过了169ng/ml。超出了该芯片像素分析的上限值255。遇到这种情况时,检测血清可通过加倍稀释高浓度AFP血清,再检测,到该血清的实际AFP浓度。
Claims (11)
1.一种检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片,其特征在于:所述蛋白芯片的基质载片上至少包括一个检测亚区,一个所述检测亚区检测一份血清样品;
所检测亚区内设置有2个检测斑区域和1个排对照斑区域,其中一个检测斑区域有固定甲胎蛋白的特异性抗体形成的检测斑,另一个检测斑区域有固定小扁豆素形成的检测斑,所述对照斑区域有固定牛血清白蛋白形成的对照斑;
同一个检测斑区域内的所有检测斑上的物质的浓度相同。
2.根据权利要求1所述的化学发光蛋白芯片,其特征在于:所述一个检测斑区域至少包括两个所述检测斑。
3.根据权利要求1所述的化学发光蛋白芯片,其特征在于:所述甲胎蛋白的特异性抗体为鼠抗人甲胎蛋白抗体。
4.根据权利要求1所述的化学发光蛋白芯片,其特征在于:所述基质载片上具有多个所述检测亚区,所述每个检测斑区域包括排列成1排的4个检测斑,所述对照斑区域包括排列成1排的4个对照斑;所述检测斑和对照斑排成平行的三列。
5.根据权利要求4所述的化学发光蛋白芯片,其特征在于:所述检测亚区之间设置有凸起作为物理隔断。
6.一种检测血清糖蛋白岩藻糖指数的化学发光试剂盒,其特征在于:包括权利要求1~4任一所述的化学发光蛋白芯片。
7.根据权利要求6所述的化学发光试剂盒,其特征在于:还包括AFP标准品,生物素标记的AFP多克隆抗体,亲和素HRP和HRP化学发光底物液;所述生物素标记的AFP多克隆抗体为兔源抗体,与所述检测斑上固定的AFP特异性抗体来源于不同物种。
8.根据权利要求6所述的化学发光试剂盒,其特征在于:还包括用于洗涤和稀释的常规试剂PBST和PBS。
9.权利要求6-8任一所述的试剂盒在检测甲胎蛋白和/或岩藻糖基化甲胎蛋白和/或血清糖蛋白岩藻糖指数方面的应用。
10.一种定量检测岩藻糖基化蛋白的方法,其特征在于:采用权利要求1~5任一所述的化学发光蛋白芯片,包括如下步骤:
(1)样品检测
将待测血清样本稀释后滴加在所述化学发光蛋白芯片的检测亚区上,孵育,然后用PBST洗涤检测亚区,去除非特异结合物;
加入用PBS稀释的生物素标记的AFP抗体,孵育,然后用PBST洗涤,去除非特异结合物;
加入PBS稀释的亲和素HRP,孵育,然后用PBST洗涤,去除非特异结合物;
加入HRP底物发光液,用化学发光扫描仪对蛋白芯片进行扫描,分别得到稀释后待测血清样本中的甲胎蛋白的发光像素值以及岩藻糖基化蛋白的发光像素值;
(2)获取甲胎蛋白标准曲线方程及岩藻糖基化蛋白的标准曲线方程:
所述甲胎蛋白标准曲线方程的横坐标x为AFP标准品的梯度浓度值;其纵坐标y为以剃度浓度的AFP标准品为系列待测样品,以步骤(1)的方法检测得到的甲胎蛋白的发光像素值;
所述岩藻糖基化蛋白标准曲线方程的横坐标x为AFP-L3标准品中AFP-L3的梯度浓度值;其纵坐标y为以剃度浓度的AFP-L3标准品为系列待测样品,以步骤(1)的方法检测得到的岩藻糖基化蛋白的发光像素值;所述AFP-L3标准品为含有岩藻糖基蛋白(AFP)的血清;
(3)步骤(1)中的待测血清样品的甲胎蛋白的发光像素值带入所述甲胎蛋白标准曲线方程中计算得到稀释后血清的甲胎蛋白浓度,乘以稀释倍数得到待测血清甲胎蛋白浓度;步骤(1)中的待测血清样品的岩藻糖基化蛋白的发光像素值带入所述岩藻糖基化蛋白标准曲线方程中计算得到稀释后的血清的岩藻糖基化蛋白浓度,乘以稀释倍数得到待测血清岩藻糖基化蛋白的浓度;
待测血清岩藻糖基化蛋白的浓度与所述待测血清甲胎蛋白浓度的比值岩藻糖基化指数。
11.根据权利要求10所述的方法,所述孵育指37℃孵育30分钟。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410772665.4A CN104678103A (zh) | 2014-08-05 | 2014-12-12 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
CN201510058591.2A CN104849468B (zh) | 2014-08-05 | 2015-02-04 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
CA2882151A CA2882151C (en) | 2014-08-05 | 2015-02-16 | Chemiluminescent protein chip, method and kit for detecting seroglycoid fucosylation index |
JP2015033234A JP6082767B2 (ja) | 2014-08-05 | 2015-02-23 | 化学発光タンパク質チップ測定方法及びそれに用いられる試薬キット |
KR1020177006041A KR20170040318A (ko) | 2014-08-05 | 2015-07-17 | 혈청 당단백질 푸코오스 지수를 검측하는 화학 발광 단백질 칩, 키트 및 이의 검측방법 |
SE1750227A SE1750227A1 (en) | 2014-08-05 | 2015-07-17 | Chemiluminescent Protein Chip, KIT and Method for DetectingSeroglycoid Fucose Index |
GB1703351.5A GB2548978B (en) | 2014-08-05 | 2015-07-17 | A chemiluminescent protein chip seroglycoid fucosylations index assay comprising AFP specific antibodies and Lens culinaris lectin |
KR1020187009587A KR101914673B1 (ko) | 2014-08-05 | 2015-07-17 | 혈청 당단백질 푸코오스 지수를 검측하는 화학 발광 단백질 칩, 키트 및 이의 검측방법 |
PCT/CN2015/084356 WO2016019797A1 (zh) | 2014-08-05 | 2015-07-17 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2014103814618 | 2014-08-05 | ||
CN201410381461 | 2014-08-05 | ||
CN201410772665.4A CN104678103A (zh) | 2014-08-05 | 2014-12-12 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104678103A true CN104678103A (zh) | 2015-06-03 |
Family
ID=53313448
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410772665.4A Pending CN104678103A (zh) | 2014-08-05 | 2014-12-12 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
CN201510058591.2A Expired - Fee Related CN104849468B (zh) | 2014-08-05 | 2015-02-04 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510058591.2A Expired - Fee Related CN104849468B (zh) | 2014-08-05 | 2015-02-04 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160223556A1 (zh) |
JP (1) | JP6082767B2 (zh) |
KR (2) | KR20170040318A (zh) |
CN (2) | CN104678103A (zh) |
AU (1) | AU2016101432A4 (zh) |
CA (1) | CA2882151C (zh) |
GB (1) | GB2548978B (zh) |
SE (1) | SE1750227A1 (zh) |
WO (1) | WO2016019797A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019797A1 (zh) * | 2014-08-05 | 2016-02-11 | 首都医科大学附属北京佑安医院 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
CN106248959A (zh) * | 2016-07-21 | 2016-12-21 | 首都医科大学附属北京佑安医院 | 一种检测血清岩藻糖蛋白的免疫渗滤方法及免疫渗滤装置 |
CN107857815A (zh) * | 2016-05-31 | 2018-03-30 | 希森美康株式会社 | 与糖肽反应的单克隆抗体及其用途 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102166711A (zh) * | 2010-02-26 | 2011-08-31 | 昆山巨仲电子有限公司 | 散热器的制作方法及其散热器 |
CN105785043B (zh) * | 2016-04-06 | 2018-02-02 | 上海良润生物医药科技有限公司 | 用于定量检测afp‑l3%的试剂盒 |
CN106198998A (zh) * | 2016-06-30 | 2016-12-07 | 深圳市亚辉龙生物科技股份有限公司 | 人甲胎蛋白异质体3化学发光免疫检测试剂盒及其制备方法 |
CN107727864A (zh) * | 2016-07-01 | 2018-02-23 | 首都医科大学附属北京佑安医院 | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 |
CN107748261A (zh) * | 2017-06-30 | 2018-03-02 | 首都医科大学附属北京佑安医院 | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 |
CN107525937A (zh) * | 2017-08-25 | 2017-12-29 | 苏州优函信息科技有限公司 | 基于上转换发光标记物、蛋白芯片及检测方法 |
CN108872594A (zh) * | 2018-07-05 | 2018-11-23 | 潍坊市康华生物技术有限公司 | 一种甲胎蛋白检测试剂盒及其制备方法 |
CN111665235A (zh) * | 2019-03-08 | 2020-09-15 | 上海索昕生物科技有限公司 | 一种化学发光微阵列芯片及其应用 |
CN116162538B (zh) * | 2022-12-16 | 2024-01-26 | 中国科学院苏州生物医学工程技术研究所 | 一种同时检测蛋白和rna的微流控芯片及试剂盒 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0718875B2 (ja) * | 1987-06-19 | 1995-03-06 | ヤマサ醤油株式会社 | 血中または体液中の微量物質含有量の測定法 |
JPH07325083A (ja) * | 1994-05-31 | 1995-12-12 | Nakarai Tesuku Kk | 糖タンパク質の特定糖鎖割合の測定方法 |
DE19806185C2 (de) * | 1998-02-02 | 1999-11-18 | Biogenes Gmbh | Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe |
JP3833955B2 (ja) * | 2002-03-27 | 2006-10-18 | 株式会社東芝 | 光導波路型プロテインチップおよびプロテイン検出装置 |
CA2481420A1 (en) * | 2002-04-05 | 2003-10-23 | University Of Georgia Research Foundation | Method for cleaving and deglycosylating antibodies to promote ligand binding |
GB0212391D0 (en) * | 2002-05-29 | 2002-07-10 | Axis Shield Asa | Assay |
CN2613759Y (zh) * | 2003-03-31 | 2004-04-28 | 穆海东 | 一种蛋白质芯片 |
GB2404734A (en) * | 2003-08-05 | 2005-02-09 | Secr Defence | A method of screening a sample for abnormally glycosylated and/or expressed proteins |
JP4374447B2 (ja) * | 2003-12-25 | 2009-12-02 | 独立行政法人産業技術総合研究所 | タンパク質と糖鎖との相互作用を分析する方法 |
US20090042734A1 (en) * | 2005-03-25 | 2009-02-12 | Ngk Insulators, Ltd. | Probe Array and Method for Producing Probe Array |
JP2007132866A (ja) * | 2005-11-11 | 2007-05-31 | Toyota Central Res & Dev Lab Inc | 反応アレイ |
US7828949B2 (en) * | 2005-12-08 | 2010-11-09 | Electronics And Telecommunications Research Institute | Biomolecule detection device, mobile phone for biomolecule detection, and biomolecule detection method |
JP4711190B2 (ja) * | 2006-07-28 | 2011-06-29 | 国立大学法人 東京大学 | グリコシル化異常症の検査方法 |
JP5109001B2 (ja) * | 2007-02-27 | 2012-12-26 | 株式会社J−オイルミルズ | α1,6フコース糖鎖の検出および分別方法 |
CN101308141B (zh) * | 2007-05-16 | 2012-08-29 | 陕西北美基因股份有限公司 | 一种分析糖蛋白的方法 |
CN101266251A (zh) * | 2008-04-25 | 2008-09-17 | 南通大学附属医院 | 玻璃微柱亲和层析测定肝癌特异性afp的方法 |
CN101603966A (zh) * | 2008-06-12 | 2009-12-16 | 上海裕隆生物科技有限公司 | 一种男性多肿瘤标志物检测蛋白芯片及其试剂盒 |
EP2204651A1 (en) * | 2009-01-06 | 2010-07-07 | Shiming Lin | Electrosensing antibody-probe detection and measurement sensor and method |
JP2010236997A (ja) * | 2009-03-31 | 2010-10-21 | Panasonic Corp | マイクロアレイ及びこれを用いた生体情報測定方法 |
EP2950098A1 (en) * | 2009-07-14 | 2015-12-02 | National Institute of Advanced Industrial Science and Technology | Glycan markers as measure of disease state of hepatic diseases |
CN102043046B (zh) * | 2009-10-13 | 2014-05-07 | 张志丽 | 一种检测糖链异常IgA肾病的蛋白芯片 |
WO2011089988A1 (ja) * | 2010-01-21 | 2011-07-28 | 株式会社J-オイルミルズ | 膵臓癌の検出方法 |
CN102081100B (zh) * | 2010-07-20 | 2015-06-24 | 李伯安 | 一种肝癌多标志物微阵列试剂盒、其制备方法及其应用 |
JP5648613B2 (ja) * | 2011-09-12 | 2015-01-07 | コニカミノルタ株式会社 | 表面プラズモン励起増強蛍光分光法用センサチップおよびそれを用いた測定方法 |
WO2013038914A1 (ja) * | 2011-09-15 | 2013-03-21 | コニカミノルタホールディングス株式会社 | 表面プラズモン共鳴及び表面プラズモン励起増強蛍光分光法を用いた特定のアナライトの定量測定方法 |
JP5726038B2 (ja) * | 2011-09-30 | 2015-05-27 | コニカミノルタ株式会社 | 表面プラズモン励起増強蛍光分光法を用いた前立腺特異抗原の定量方法 |
JP5991032B2 (ja) * | 2012-06-07 | 2016-09-14 | コニカミノルタ株式会社 | レクチンを用いたアナライトの検出方法 |
CN103822878A (zh) * | 2012-11-16 | 2014-05-28 | 上海市肿瘤研究所 | 凝集素功能化的纳米金及其制备方法和应用 |
CN103336126B (zh) * | 2013-05-08 | 2015-12-02 | 西北大学 | 一种针对唾液样本的凝集素测试芯片及其处理方法 |
CN103823058B (zh) * | 2014-02-27 | 2016-02-03 | 首都医科大学附属北京佑安医院 | 血清中抗原类蛋白的化学发光蛋白芯片方法和试剂盒 |
CN104678103A (zh) * | 2014-08-05 | 2015-06-03 | 首都医科大学附属北京佑安医院 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
-
2014
- 2014-12-12 CN CN201410772665.4A patent/CN104678103A/zh active Pending
-
2015
- 2015-02-04 CN CN201510058591.2A patent/CN104849468B/zh not_active Expired - Fee Related
- 2015-02-13 US US14/622,259 patent/US20160223556A1/en not_active Abandoned
- 2015-02-16 CA CA2882151A patent/CA2882151C/en not_active Expired - Fee Related
- 2015-02-23 JP JP2015033234A patent/JP6082767B2/ja not_active Expired - Fee Related
- 2015-07-17 WO PCT/CN2015/084356 patent/WO2016019797A1/zh active Application Filing
- 2015-07-17 SE SE1750227A patent/SE1750227A1/sv not_active Application Discontinuation
- 2015-07-17 GB GB1703351.5A patent/GB2548978B/en not_active Expired - Fee Related
- 2015-07-17 KR KR1020177006041A patent/KR20170040318A/ko active Application Filing
- 2015-07-17 KR KR1020187009587A patent/KR101914673B1/ko active IP Right Grant
-
2016
- 2016-08-10 AU AU2016101432A patent/AU2016101432A4/en not_active Ceased
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016019797A1 (zh) * | 2014-08-05 | 2016-02-11 | 首都医科大学附属北京佑安医院 | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 |
GB2548978A (en) * | 2014-08-05 | 2017-10-04 | Beijing Youan Hospital Capital Medical Univ | Chemiluminescence protein chip, kit and method for detecting seroglycoid fucose index |
GB2548978B (en) * | 2014-08-05 | 2019-08-21 | Beijing Youan Hospital Capital Medical Univ | A chemiluminescent protein chip seroglycoid fucosylations index assay comprising AFP specific antibodies and Lens culinaris lectin |
CN107857815A (zh) * | 2016-05-31 | 2018-03-30 | 希森美康株式会社 | 与糖肽反应的单克隆抗体及其用途 |
CN106248959A (zh) * | 2016-07-21 | 2016-12-21 | 首都医科大学附属北京佑安医院 | 一种检测血清岩藻糖蛋白的免疫渗滤方法及免疫渗滤装置 |
WO2018014709A1 (zh) * | 2016-07-21 | 2018-01-25 | 首都医科大学附属北京佑安医院 | 一种检测血清岩藻糖蛋白的免疫渗滤方法及免疫渗滤装置 |
CN106248959B (zh) * | 2016-07-21 | 2019-01-25 | 首都医科大学附属北京佑安医院 | 一种检测血清岩藻糖蛋白的免疫渗滤方法及免疫渗滤装置 |
Also Published As
Publication number | Publication date |
---|---|
AU2016101432A4 (en) | 2016-09-08 |
GB201703351D0 (en) | 2017-04-19 |
KR20180039184A (ko) | 2018-04-17 |
KR101914673B1 (ko) | 2018-11-02 |
KR20170040318A (ko) | 2017-04-12 |
GB2548978A8 (en) | 2018-10-10 |
GB2548978B (en) | 2019-08-21 |
CN104849468B (zh) | 2018-02-13 |
JP2016038375A (ja) | 2016-03-22 |
WO2016019797A1 (zh) | 2016-02-11 |
SE1750227A1 (en) | 2017-03-02 |
US20160223556A1 (en) | 2016-08-04 |
CN104849468A (zh) | 2015-08-19 |
CA2882151A1 (en) | 2016-02-02 |
JP6082767B2 (ja) | 2017-02-15 |
CA2882151C (en) | 2017-10-03 |
GB2548978A (en) | 2017-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104849468B (zh) | 检测血清糖蛋白岩藻糖指数的化学发光蛋白芯片、试剂盒及检测方法 | |
CN108333344A (zh) | 高灵敏度的化学发光免疫分析试剂盒及其制备方法和应用 | |
Wu et al. | Sensitive time-resolved fluoroimmunoassay for simultaneous detection of serum thyroid-stimulating hormone and total thyroxin with Eu and Sm as labels | |
CN103033619A (zh) | 一种综合检测肺癌标志物的蛋白质芯片试剂盒及方法 | |
CN103823058B (zh) | 血清中抗原类蛋白的化学发光蛋白芯片方法和试剂盒 | |
CN106771239A (zh) | 血清淀粉样蛋白a/降钙素原/c‑反应蛋白三合一测定试剂盒及制法 | |
Park et al. | Comparison of four automated carcinoembryonic antigen immunoassays: ADVIA Centaur XP, ARCHITECT I2000sr, Elecsys E170, and Unicel Dxi800 | |
Chang et al. | Comparative evaluation and measure of accuracy of ELISAs, CLIAs, and ECLIAs for the detection of HIV infection among blood donors in China | |
Xiao et al. | Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis. | |
CN106872716A (zh) | 血清淀粉样蛋白a和降钙素原二合一测定试剂盒及制法 | |
CN104569374B (zh) | 一种快速定量检测c‑反应蛋白的均相荧光免疫试剂组及其制备方法 | |
CN107703315A (zh) | 叶酸检测试剂盒及其制备方法 | |
CN107907694A (zh) | 抗穆勒氏管激素检测试剂盒及其制备方法 | |
CN106771264A (zh) | 促甲状腺激素测定试剂盒及制作方法 | |
CN1987468A (zh) | 血管内皮生长因子时间分辨荧光免疫分析方法及试剂盒 | |
Wu et al. | Matrix interference in serum total thyroxin (T4) time-resolved fluorescence immunoassay (TRFIA) and its elimination with the use of streptavidin–biotin separation technique | |
CN107748261A (zh) | 一种检测血清中异常脱羧凝血酶原的蛋白芯片、试剂盒及其制备方法 | |
CN107436350B (zh) | 一种利用酶标板和单克隆抗体进行混合物中各成分的分离方法 | |
Yang et al. | Development of a novel parallel determination platform: a feasibility study tested on a chemiluminescence device | |
Sheng et al. | Simultaneous determination of α‐fetoprotein immune complexes and α‐fetoprotein concentration in hepatocellular carcinoma using dual‐label time‐resolved immunofluorometric assays | |
Darwish et al. | Enzyme-linked immunosorbent assay for 2-deoxycytidine | |
Pu et al. | Development and Evaluation of a Combined Immunoassay Method Based on a Stable Isotope Tagging Strategy and Inductively Coupled Plasma Mass Spectrometry for Detecting Human Chorionic Gonadotropin. | |
CN103293313A (zh) | 糖类抗原15-3时间分辨免疫荧光分析法及试剂盒 | |
RU2702900C1 (ru) | Способ количественного определения антител к бензо[а]пирену в биологических жидкостях человека | |
Boerman et al. | Time-resolved immunofluorometric assay for the ovarian carcinoma-associated antigenic determinant CA 125 in serum. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication |